Company Encyclopedia
View More
name
CHENGDA PHARMA
301201.SZ
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates.
3.096 T
301201.SZMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking193/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-2.37%D
    • Profit Margin-13.81%D
    • Gross Margin48.75%B
  • Growth ScoreD
    • Revenue YoY-5.87%D
    • Net Profit YoY-173.69%E
    • Total Assets YoY-1.12%D
    • Net Assets YoY-4.51%D
  • Cash ScoreD
    • Cash Flow Margin-723.96%E
    • OCF YoY-5.87%D
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreA
    • Gearing Ratio9.98%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CHENGDA PHARMA: Elected Ge Jianli as Chairman

    36Kr learned that CHENGDA PHARMA announced that the board meeting agreed to elect Ge Jianli as the chairman of the company and the director representing the company's executive affairs, agreed to appoint Lu Gang as the general manager, and appointed Peng Zhiyong, Huang Honglin, Lu Jin, Yang Xiaojing, Hu Bao, and Zhao Minwei as deputy general managers, and appointed Fei Chao as the financial director

    36Kr·
    SZ
    301201
    -0.86%
    36Kr·
    SZ
    301201
    -0.86%

    CHENGDA PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 16.7733 million yuan, a decrease of 58.47%

    CHENGDA PHARMA released its third-quarter report for 2025, with operating revenue of 285 million yuan in the first three quarters, a year-on-year increase of 16.95%. The net profit attributable to the parent company was 16.7733 million yuan, a year-on-year decrease of 58.47%; the net profit after deducting non-recurring gains and losses was 3.9025 million yuan, a year-on-year decrease of 72.96%. The basic earnings per share were 0.1107 yuan

    Zhitong·
    SZ
    301201
    -0.86%
    Zhitong·
    SZ
    301201
    -0.86%

    CHENGDA PHARMA: Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings by no more than 7.27%

    CHENGDA PHARMA announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings by no more than 7.27%, approximately 11.0069 million shares, through centralized bidding or block trading from September 29, 2025, to December 28, 2025, within a 3-month period

    Zhitong·
    SZ
    301201
    -0.86%
    Zhitong·
    SZ
    301201
    -0.86%

    Shibeikang announced the completion of Series B financing, with listed company CHENGDA PHARMA as the exclusive strategic investor

    Recently, Chengdu Shibeikang Biopharmaceutical Technology Co., Ltd. announced the completion of its Series B financing. This round of financing was exclusively strategically invested by the listed company CHENGDA PHARMA. The funds raised will mainly be used to accelerate the construction of the R&D pipeline, expand the R&D laboratory, and promote the international application process of core products. According to Shibeikang, in its early entrepreneurial stage, it also received investments from industrial investors such as Fosun Pharma and Chuan Chuang Investment, as well as local investment institutions

    Zhitong·
    SZ
    301201
    -0.86%
    Zhitong·
    SZ
    301201
    -0.86%

    CHENGDA PHARMA released its performance for the first half of the year, with a net profit attributable to the parent company of 12.8244 million yuan, a year-on-year decrease of 49.06%

    CHENGDA PHARMA released its semi-annual report for 2025, with operating revenue of 182 million yuan, a year-on-year increase of 11.24%. However, the net profit attributable to shareholders of the listed company was 12.8244 million yuan, a year-on-year decrease of 49.06%. The net profit after deducting non-recurring gains and losses was 2.899 million yuan, a year-on-year decrease of 8.37%. The basic earnings per share were 0.0847 yuan

    Zhitong·
    SZ
    301201
    -0.86%
    Zhitong·
    SZ
    301201
    -0.86%
    © 2025 Longbridge｜Disclaimer